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Background: Myocardial infarction remains the leading cause of mortality in developed countries despite recent
advances in its prevention and treatment. Regenerative therapies based on resident cardiac progenitor cells (CPCs)
are a promising alternative to conventional treatments. However, CPCs resident in the heart are quite rare. It is
unclear how these CPCs can be isolated and cultured efficiently and what the effects of long-term culture in vitro
are on their ‘stemness’ and differentiation potential, but this is critical knowledge for CPCs’ clinical application.
Results: Here, we isolated stem cell antigen-1 positive cells from postnatal mouse heart by magnetic active cell sorting
using an iron-labeled anti-mouse Sca-1 antibody, and cultured them long-term in vitro. We tested stemness marker
expression and the proliferation ability of long-term cultured Sca-1+ cells at early, middle and late passages. Furthermore,
we determined the differentiation potential of these three passages into cardiac cell lineages (cardiomyocytes,
smooth muscle and endothelial cells) after induction in vitro. The expression of myocardial, smooth muscle and
endothelial cell-specific genes and surface markers were analyzed by RT-PCR and IF staining. We also investigated the
oncogenicity of the three passages by subcutaneously injecting cells in nude mice. Overall, heart-derived Sca-1+ cells
showed CPC characteristics: long-term propagation ability in vitro, non-tumorigenic in vivo, persistent expression of
stemness and cardiac-specific markers, and multipotent differentiation into cardiac cell lineages.
Conclusions: Our research may bring new insights to myocardium regeneration, for which even a small number of
biopsy-derived CPCs could be enriched and propagated long term in vitro to obtain sufficient seed cells for cell
injection or cardiac tissue engineering.
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Despite recent progress in prevention and therapies,
heart failure resulting from acute myocardial infarction
or chronic myocardial ischemia remains the leading cause
of mortality in developed countries [1]. The central cellu-
lar mechanism underlying myocardial dysfunction is an ir-
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Heart transplantation remains the final therapeutic option
for end-stage heart failure [4], but is limited by donor
organ shortages and life-threatening complications, includ-
ing organ rejection and side effects of pharmacological im-
mune suppression. Regenerative therapies, including cell
injection and myocardial tissue engineering, have been
pursued as new possibilities to repair the damaged myo-
cardium. Over the last decade, much research has focused
on finding the ideal cell type to mediate myocardial repair.
To date, cells derived from fetal or neonatal hearts have
been applied to damaged myocardia to regenerate myocar-
dial tissues in animal studies [5,6], but a similar approach
in humans poses ethical issues and may be insufficient totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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clinical use [7]. Developing methods to use stem cell-
derived cardiomyocytes may be required.
The recent discovery of resident cardiac progenitor
cells (CPCs) in the postnatal heart has marked a new era
of cardiac regenerative medicine. Several laboratories have
identified distinct populations of CPCs including side
population (SP) cells [8], stem cell antigen-1-positive
(Sca-1+) cells [9], c-kit-positive (c-kit+) cells [10], Islet-
1-positive (Isl-1+) cells [11,12], Wilms’ tumor 1-positive
(WT1+) epicardial progenitor cells [13], and cardiosphere-
derived cells (CDCs) [14]. However, the levels of resident
CPCs in postnatal heart are limited and there is a clear
negative correlation between CPC number and age [15].
Furthermore, in clinical practice, CPCs may be more likely
to be isolated from catheter-based tiny biopsy specimens
rather than large masses of cardiac tissue. Yet, large quan-
tities of CPCs are needed for myocardium regeneration.
Goumans’ team has developed a method for efficient
isolation and expansion of human CPCs from cardiac
surgical waste by magnetic cell sorting (MACS) and has
developed a detailed protocol for very efficient in vitro
differentiation of CPCs into cardiomyocytes (80–90%
differentiation) [16]. However, it is unclear how many
seed cells would be eventually obtained for regenerative
therapies and whether their ‘stemness’ or differentiation
potential would decline with long-term culture in vitro.
In this report, we isolated Sca-1+ cells from postnatal
mouse heart by MACS using an iron-labeled anti-mouse
Sca-1 antibody, and cultured the cells long-term in vitro.
To monitor the stemness and differentiation potential of
long-term cultured Sca-1+ cells, we selected the 7th, 28th,
and 53th passages to test early, middle and late phases of
culture. We further identified these cells as Sca-1+/CD31−
CPC subpopulations, which are able to proliferate over
the long-term in vitro without a detectable decline in
stemness. In addition, they retain the potential to differen-
tiate into multiple cardiac cell lineages.
Results
Isolation and in vitro culture of postnatal mouse heart-
derived Sca-1+ cells
MACS is an efficient system for cell isolation, especially
for rare cells in tissues [17]. We used this system to isolate
resident stem cells from postnatal mice hearts, based on
the expression of the surface marker stem cell antigen
Sca-1 (Figure 1A). To verify the efficiency of MACS using
an iron-labeled anti-Sca-1 antibody, we performed FCM
to analyze the enrichment of Sca-1+ cells in samples
before and after MACS. Pre-MACS, just after filtration
through a 40-μm cell strainer, the whole cardiac cell
suspension was composed of approximately 3.2% Sca-1+
cells. After MACS, the Sca-1+-enriched population
contained approximately 85% Sca-1+ cells, and theflow-through population contained only 0.1% Sca-1+
cells (Figure 1B). Viewed with an inverted microscopy
in ordinary light, cells in Sca-1+-enriched populations
were sparse, with quasi-circular or oval morphology
and homogenous in size, while cells in flow-through
populations were crowded, containing diverse cell types
and sizes (Figure 1B). Thus, the efficiency and specificity
of MACS were considered reasonable.
After seeding on gelatin-coated 12-well dishes, the
long-term cell culture of Sca-1+-enriched population
was initiated. After about one week, small, flat, spindle-
shaped cells appeared and grew gradually. Many of these
cells were phase-bright under white light. On day 36, the
primary cells (P0) had grown to approximately 90% con-
fluence and were propagated to P1 at 1:2, that is, trans-
ferred from one well of the 12-well dish (4.5 cm2) to one
well in a 6-well dish (9.6 cm2), also coated with gelatin.
About 4 days after the first passage, cells of P1 were
detached and further subcultured as P2 at 1:5; cells were
transferred from one well of the 6-well dish (9.6 cm2) to
one 9-cm dish (49 cm2) without gelatin coating. P2 cells
were cultured in normal medium for 4 weeks, at which
point they reached 90% confluence and were split at 1:2
to P3. P3 grew more rapidly and was split after about
1 week. From then on, the subcultured cells were pas-
saged every 3–4 days at different ratios. The Sca-1+ cells
were passaged to over P90 and still grew well with phase-
brightness (data not shown). There were no noticeable
changes in gross morphology until at least P53 (repre-
senting a period of 245 days; Figure 1C).
Surface characteristics of Sca-1+-enriched long-term cell
culture
To identify the surface characteristics of heart-derived
Sca-1+-enriched cells and determine whether these
would change during long-term in vitro culture, cells of
P7, P28, and P53 were analyzed for stem cell antigen
Sca-1 and other cell surface markers by FCM and IF
staining. FCM analysis showed that the percentage of
Sca-1+ cells increased from 91.2% to 99.9% over P7 to
P53. This indicates that not only do the Sca-1+-enriched
passages still mainly consist of Sca-1+ cells, but the purity
of Sca-1+ cells increases with passaging. Few cells were
detected that expressing c-kit, another stem cell marker;
proportions varied from 0.3-0.6%. Flk-1, an endothelial
progenitor cell marker, was also barely expressed. CD34, a
hematopoietic progenitor cell marker [18], was initially
expressed in 11.6% of P7 cells, which declined to 1.3% of
cells at P53. CD31, a marker of endothelial cells [19,20]
and CD45, a marker of the hematopoietic lineage [17]
were also both rarely expressed (Figure 2).
To further characterize the Sca-1+ cells, we double
labeled them with antibodies against Sca-1 and CD31
(Figure 3), because Sca-1+/CD31− CPCs show functional
Figure 1 Isolation and enrichment of Sca-1+ cells from the mouse heart and in vitro culture. A. Schematic representation of the isolation
and enrichment of Sca-1+ cell populations from the mouse heart. B. Efficiency and feasibility of MACS. The proportion of Sca-1+ cells contained in
pre-MACS population, Sca-1+-enriched population, and flow-through population analyzed by flow cytometry. The lower two panels show the
morphology of cells after MACS under ordinary light microscopy (×100). C. Cells of Sca-1+-enriched populations cultured and passaged in vitro.
Morphology of cells under inverted microscopy. Scale bar = 200 μm.
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do not [21]. Based on FCM, there was strong expression of
Sca-1 in cells at P7, P28, and P53, but few was Sca-1+/CD31+
cells (Figure 3A), which was confirmed by IF staining. IF
staining showed that few cells expressed CD31 in Sca-1+
enriched cell populations (Figure 3B). These data indicatethat the mouse heart-derived Sca-1+ cells isolated here
represent a Sca-1+/CD31− subpopulation.
Gene expression profile of Sca-1+-enriched cells
To further characterize gene expression in the long-term
cultured Sca-1+-enriched cells, gene expression profiles
Figure 2 Surface marker expression profiles of three subcultures derived from Sca-1+-enriched populations analyzed by flow
cytometry. All populations were analyzed for the expression of the stem/progenitor cell markers Sca-1 and c-kit, endothelial progenitor cell
marker flk-1, endothelial cell specific marker CD31, hematopoietic progenitor marker CD34, and hematopoietic lineage marker CD45. Black line,
non-stained cells; red line, corresponding antibody. (n = 3).
Wang et al. BMC Biotechnology 2014, 14:75 Page 4 of 11
http://www.biomedcentral.com/1472-6750/14/75of P7, P28, and P53 were generated by RT-PCR. Two
pluripotent stem cell specific genes, Nanog and tel-
omerase reverse transcriptase (TERT) [17], were both
expressed; TERT is usually not detectable in cardiac
fibroblasts [22]. Islet-1 (ISL-1), a marker of the second-
ary heart field [15], and TBX5, a marker of the primary
heart field [17] were both detected, though the expres-
sion level of TBX5 was weaker than that of ISL-1. The
cardiac-specific transcription factors GATA-4, Nkx-2.5,
and MEF2C were all expressed in three different passages.
In contrast, the mature cardiomyocyte structural gene car-
diac α-myosin heavy chain (α-MHC) [17] was undetect-
able (Figure 4A). These results indicate that the long-term
cultured cardiac-derived Sca-1+-enriched cells show
cardiac-specific features, but are not mature cardio-
myocytes or cardiac fibroblasts.
In vitro proliferation capacity and tumorigenicity in vivo
The ability to proliferate is a significant feature of stem
cells and progenitor cells. The proliferative abilities of
P7, P28, and P53 cells were indirectly assessed by meas-
uring the OD value of the supernatant incubated with
CCK-8. Five sequential time points were chosen for
testing: days 1 (24 hours after seeding), 3, 5, 7 and 9. At
day 1 of each passage, the OD value was generally low
and there was no statistical difference among these three
passages. But from day 1 to day 3, it sharply increased.After day3, the OD value continued increasing slowly,
peaked at day 7, then plateaued at this level for several
days (Figure 4B). There was no statistical difference in
proliferation between P7 and P28. However, the OD
value at day 3, day 5, day 7, and day 9 of P53 was signifi-
cantly higher than that of P7 and P28(*p < 0.01). And in
all the comparisons between two adjacent time points in
each passage, only day 1 and day 3 presented statistical
difference (#p < 0.01). These data indicate that the prolif-
erative ability has increased during long term culture,
and the significant time point is day 3.
To exclude that Sca-1+ cells were spontaneously
transforming into tumorigenic cells, cells from P7, P28,
and P53 were injected subcutaneously into SCID mice.
Equivalent mouse R1 ES cells were injected contralaterally
as a positive control. No tumors developed at the site of
implantation of P7, P28, or P53 cells over approximately
3 months. In contrast, sites injected with R1 ES cells all
developed neoplasms about 3 weeks after injection;
3 months later, these tumors were nearly 20 mm in diam-
eter. The tumorigenic rates are shown in Additional file 1:
Table S1.
Multipotent differentiation of mouse heart-derived Sca-1+
cells into cardiac cell lineages
To estimate the differentiation potential of cells into the
cardiomyocyte, smooth muscle, and endothelial lineages,
Figure 3 Analysis of CD31 expression in Sca-1+ cells by FCM and identification of Sca-1+-enriched cells by IF staining. A. Flow cytometry
analyzed the expression of surface markers CD31 in Sca-1+ cells. B. All cells were triple-stained for Sca-1 (green), CD31 (red), and DAPI (blue).
Bar = 100 μm.
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ation medium, with simultaneously cultured in differenti-
ation medium without growth factors serving as controls.
When induction was completed, lineage-specific markers
were analyzed by IF staining and RT-PCR.
After 2 weeks of induction to a cardiomyocyte fate,
cMHC-positive and cTNT-positive cells were detected
in all three passages, and no cMHC- or cTNT-positive
cells were observed in control groups (Figure 5A,B).
Though the differentiation potential in quantitative ana-
lysis of these three passages didn’t present statistical differ-
ence among them, it was still low in each passage
(Additional file 2: Figure S1A). This cardiomyogenic
potential was confirmed by their gene expression profiles.
Mature cardiomyocyte marker genes, including cardiac
α-myosin heavy chain (α-MHC), cardiac β-myosin heavy
chain (β-MHC), myosin light chain-2a (MLC-2a) and my-
osin light chain-2v (MLC-2v) were expressed in induced
cells. In contrast, these genes were not expressed in
control groups. After differentiation, the cardiac-specific
transcription factor GATA4 was downregulated, while
Nkx2.5 and MEF2C were upregulated (Figure 5C).
After 10 days of induction to a smooth muscle cell fate,
SMA-positive and sMHC-positive cells were detected and
the number of calponin-positive cells increased signifi-
cantly compared to the control groups (Figure 6A-C).
And the differentiation potential in quantitative analysis ofthese three passages didn’t present statistical differences
among them (Additional file 2: Figure S1B). This result
was further verified by examining the gene expression
of SMA and calponin. SMA was expressed in all in-
duced passages and there was no expression in control
groups, while the expression of calponin was upregu-
lated after induction (Figure 6D).
After 2 weeks of induction to an endothelial fate,
CD31-positive cells were detected in all passages, while
none were detected in control groups (Figure 7A). And
the differentiation efficiency of these three passages didn’t
present statistical differences among them (Additional file 2:
Figure S1C). There was expression of the endothelial
specific genes CD31, VE-cadherin, and vWF in all the
induced populations, and none in the control groups.
The expression level of the endothelial progenitor cell
marker Flk-1 did not detectably change after differenti-
ation (Figure 7B). Overall, these data indicate that mouse
heart-derived Sca-1+ cells are multipotent, retaining an
ability to differentiate into different cardiac cell lineages,
despite long-term propagation in vitro.
Discussion
In this article, we successfully isolate Sca-1+ cells from
postnatal mice hearts with the MACS system, using a
microbead-labeled anti-Sca-1 antibody. The isolated Sca-1+
cells express the stemness markers Nanog and TERT, the
Figure 4 Gene expression profiles and proliferation abilities of
Sca-1 high-expressing cell populations analyzed by RT-PCR and
CCK-8. A. Expression of stem cell-related genes Nanog and TERT,
cardiac precursor-related genes ISL-1 and TBX5, early cardiogenic
genes GATA4, Nkx2.5, MEF2c, and mature cardiomyocyte specific
gene α-MHC was analyzed by RT-PCR. RNA extracted from whole
postnatal mouse heart (mH) was used as a positive control. (n = 3).
B. Proliferation abilities were tested with CCK-8. Five successive time
points were chosen: days 1 (24 hours after seeding), 3, 5, 7, and 9.
Proliferation abilities of these cell populations were indirectly
measured by the OD value at 450 nm. (n = 3). (*P < 0.01 vs P7, P28;
#P < 0.01 vs d1).
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specific transcription factors GATA4, Nkx2.5, and MEF2C.
They can be propagated in vitro for a long time without
any significant changes in marker expression. Moreover,
the isolated Sca-1+ cells and their long-term descendants
exhibit multipotent differentiation to cardiac cell lineages,
including smooth muscle, endothelial cells and cardio-
myocytes. So, the Sca-1+ cells we isolated from mouse
heart tissue should be identified as CPCs.
Isolation of a cardiac progenitor cell (CPC) population
from the heart is challenging, particularly because of a
lack of specific surface markers. Though Sca-1+ cells, c-kit+
cells, Isl-1+ cells, WT1+ cells, SP cells and CDCs havebeen extracted from postnatal cardiac tissue [8-14], it
remains to be determined whether these individual CPC
populations represent different intermediate stages of a
single cell lineage or are independent cell lineages origin-
ating from different precursors. Some cell markers that
could distinguish different lineages, such as Isl-1 and WT-1,
are transcription factors, and therefore, transgenic animals
would be necessary to genetically tag these proteins to use
them as tools to isolate live cells [12,13]. Whether CDCs
possess cardiomyogenic potential remains controversial
[14,23,24]. Although c-kit+ cardiac stem cells were the first
stem cells identified in the rat heart [10], recent studies
have suggested that Sca-1+ progenitor cells are actually
the predominant stem cell population there [9,25]: Sca-1+
cells are 100–700 fold more frequent than c-kit+ cells
[10,26]. Although the biological hierarchy and correlation
between cardiac SP cells and Sca1+ cells is still unclear,
interestingly, a high percentage (>80%) of cardiac SP cells
express the Sca1 antigen and only a very small percentage
(approximately 3.6%) of cardiac Sca-1+ cells is included in
the SP fraction [9,21]. Furthermore, cardiac SP cells typic-
ally lack c-kit, in contrast to marrow SP cells [9,21]. For
these reasons, Sca-1+ cells in cardiac tissue may be the
most populous CPCs or predominate over the long-term,
and thus may be relatively easy to isolate from cardiac
tissue. This is why we aimed to isolate Sca-1+ CPCs from
the mouse heart in our research. In 3- to 4-week-old mice,
Sca-1+ cells accounted for approximately 3.2% of total car-
diac cells (Figure 1B), in line with the previously reported
3.0% [27] and 2.1% [9] of Sca-1+ cells in 8-week-old and
6- to 12- week-old mice heart respectively; there is a clear
negative correlation between CSC number and age [15].
Here, Sca-1+ cardiac cells, including early, middle and
late passages, showed limited expression of the common
stemness marker c-Kit and the hematopoietic lineage
markers CD34 and CD45, which characterize bone
marrow-derived stem cells [21]. Moreover, they also
showed limited expression of the endothelial lineage
markers Flk-1 and CD31. However, during early stages
of in vitro culture, such as P7, the expression of CD34
in enriched cells is somewhat higher than found in pre-
vious studies [17]. We ascribe this outcome to only one
round of magnetic sorting. Since CD34 has been charac-
terized as a marker of progenitor cells in several lineages,
it may represent another subpopulation of CPC or yet
another lineage. Based on FCM and IF staining (Figure 3),
these cardiac progenitor cells belonged to a Sca-1+/CD31−
subpopulation, which has been reported to show functional
cardiomyogenic differentiation [21]. Sca-1+/CD31− CPCs
may be promising starting material to produce cells for
cardiac regeneration. However, little is known about these
cells’ stemness characteristics or differentiation potential
after long-term culture in vitro. These features will deter-
mine whether it is possible to obtain sufficient seed cells
Figure 5 Differentiation potential of subcultured cells from Sca-1+-enriched populations into cardiomyocyte-like cells in vitro. A-B.
All cell populations were stained for the cardiomyocyte specific marker cardiac MHC (green), cardiac Troponin T (green) and DAPI (blue) after
induction. White arrows indicate representative cells positive for each cardiomyocyte-specific antigen. Scale bar = 50 μm. C. Expression of cardiac-specific
transcription factors GATA4 and Nkx2.5, early cardiogenic gene MEF2c, and cardiomyocyte-specific genes α-MHC, β-MHC, MLC-2a, and MLC-2v was
analyzed by RT-PCR. RNA extracted from whole postnatal mouse heart (mH) was used as a positive control.
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tures in cultured CPCs, propagating Sca-1+/CD31− CPCs
over 53 passages. If calculated from one primary isolated
cell, with a splitting ratio of 1:3, there would be approxi-
mately 2 × 1014 cells at P28 and approximately 2 × 1025
cells at P53. These quantities would be sufficient to meet
the requirements of cardiac tissue engineering.
Stemness characteristics include specific marker ex-
pression, proliferation ability, and differentiation poten-
tial. In gene expression profile analysis, Sca-1+ cardiac
cells were positive for the cardiac mesoderm precursor
markers Isl-1 and TBX5, and cardiac-specific transcrip-
tion factors Nkx2.5 and GATA4, but negative for the
cardiomyocyte structure gene α-MHC (Figure 4A). Isl-1
is a marker of cardiac precursors in the developing as
well as postnatal heart [15], and also is a marker of cells
in the secondary heart field. Isl-1+ cells are considered
to be cardiovascular precursors with the ability to differ-
entiate into the three main cardiac cell lineages [28]. In
contrast, Tbx5 is expressed in the primary heart field
[29]. Proliferation ability is another important stemness
characteristic. Here, Sca-1+ CPCs in early, middle and
late passages proliferated rapidly during days 1–3 after
seeding, with continuous growth that peaked at day 7.
These results are consistent with previous reports [17].
There were significant differences in proliferation ability
between P7, P28 and P53 during the period of rapid pro-
liferation (Figure 4B). P53 showed the greatest prolifera-
tion ability of the three. Tateishi and colleagues havereported that knockdown of Sca-1 transcripts in CPCs,
by inactivating Akt, leads to retarded ex vivo expansion
and apoptosis. That is, Sca-1 signaling might be essential
to promote CPC proliferation and survival [30]. In this
study, the purity of Sca-1+ cells was highest at P53,
which may have contributed to their greater prolifera-
tion ability. To test whether cells became tumorigenic
over long-term culture, Sca-1+ cells were injected sub-
cutaneously into nude mice: in over more than 3 months
of observation, no neoplasms appeared.
We tested the differentiation potential of Sca-1+/CD31−
cells in early, middle, and late stages of culture. After
differentiation, Sca-1+ cells presented specific marker ex-
pression patterns of multiple cardiac cell lineages, such
as sMHC, SMA and calponin for smooth muscle, CD31,
vWF and VE-cadherin for endothelial cells, and cTNT,
cMHC and MLC for cardiomyocytes (Figures 5, 6 and
7). There were no significant differences between early,
middle and late passages in differentiation potential.
This study nevertheless has some limitations. Although
the cells did present cardiomyogenic differentiation po-
tential, the frequency of cardiomyogenic differentiation
was lower than expected. Though 5-azacytidine is a clas-
sic agent to induce bone marrow-derived cells to effi-
ciently differentiate into cardiomyocytes, it appears less
effective in the Sca-1+ CPC population [17]. Previous re-
search has shown that cardiomyogenic differentiation of
Sca-1+ CPCs induced by dexamethasone, dimethylsulfox-
ide, 5-azacytidine, oxytocine, TGF-β, Wnt1, Wnt5a, BMP2,
Figure 6 Differentiation potential of subcultured cells from
Sca-1+-enriched population into smooth muscle-like cells in vitro.
A-C. All cell populations were stained for the smooth muscle specific
marker SMA (green), smooth muscle MHC (green), calponin (green)
and DAPI (blue) after induction. Scale bar = 200 μm. D. Expression of
smooth muscle specific genes α-SMA and calponin was analyzed by
RT-PCR. RNA extracted from whole postnatal mouse heart (mH) was
used as a positive control.
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ate mature, beating cardiomyocytes. Only stimulation with
BMP2 combined with FGF-4 has been shown to induce
the expression of mature cardiac markers [17]. Therefore,
we also utilized BMP2 combined with FGF-4 to induce
Sca-1+ CPCs for cardiomyogenic differentiation in our re-
search. Regardless of a failure to generate beating cardio-
myocytes, the ratio of cardiomyogenic marker expression
was still low (Additional file 2: Figure S1A). Further stud-
ies are required to identify efficient inducing factors. The
function of differentiated cells from those Sca-1+/CD31−
progenitor cells should also be investigated in the future.Conclusions
We have isolated postnatal mouse heart-derived Sca-1+/
CD31− CPCs by MACS, which can be propagated in vitro
over the long-term while retaining stemness characteris-
tics and multiple differentiation potentials. This research
may present a possibility that in future clinical studies on
cardiac regeneration we can provide a sufficient source of
seed cells from little human heart tissue.
Methods
Experimental animals and ethics statement
Wild-type ICR mice (3–4 weeks old) and nude mice
(3–4 weeks old) were used for cell isolation and subcuta-
neous cell injection, respectively. All mice were purchased
from the Shanghai Laboratory Animal Center (Shanghai
Institutes for Biological Sciences, Chinese Academy of
Sciences). The Animal Care Committee of Shanghai
Children’s Medical Center approved all procedures and
protocols. The investigation conformed to the Guide for
the Care and Use of Laboratory Animals of the Shanghai
Children's Medical Center.
Cell isolation
Whole hearts were extracted from either male or female
ICR mice, split, and washed several times with ice-cold
PBS to remove the residual blood. The hearts were
minced and digested with 0.1% collagenase type A (Roche)
at 37°C for 60 minutes, then filtered through a 40 μm cell
strainer (BD Falcon). Half of the filtered cardiac cell sus-
pension was used for flow cytometry (FCM) analysis; the
other half was centrifuged at 300 g for 5 min at 4°C to
remove the blood cells and debris in the supernatant, then
resuspended in cold M-buffer saline (containing 1% BSA;
Miltenyi Biotec). After incubation for 5 min on ice (to
remove settled cardiomyocytes), the supernatant was col-
lected in a new tube and re-centrifuged. The sample was
resuspended and an aliquot taken to determine the cell
number. The sample was then centrifuged at 300 g for
10 min at 4°C. The supernatant was aspirated completely,
and the cell pellet was resuspended in 90 μl cold M-buffer,
followed by incubation with 10 μl FITC-conjugated mono-
clonal anti-mouse Sca-1 antibody (Miltenyi Biotec) at 4°C
for 10 min. The cells were washed 3 times with cold
buffer, re-centrifuged, resuspended in 80 μl buffer, then
incubated with 20 μl microbeads-conjugated monoclonal
anti-FITC antibody(Miltenyi Biotec) for 15 min at 4°C. Cells
were then passed through a magnetic cell sorting (MACS)
column in a Miltenyi magnetic field to isolate a Sca-1+-
enriched cell suspension. All manipulations were con-
ducted with aseptic technique and MACS was performed
in the dark. Samples of the Sca-1+-enriched suspension
and the flow-through suspension were subsequently used
for flow cytometry. The residual Sca-1+-enriched cell
suspension was used for further culture. The cell isolation
Figure 7 Differentiation potential of subcultured cells from Sca-1+-enriched populations into endothelial-like cells in vitro. A. All cell
populations were stained for the endothelial cell marker CD31 (red) and DAPI (blue) after induction. Scale bar = 200 μm. B. Expression of the
endothelial progenitor gene flk-1 and the endothelial cell specific genes CD31, vWF, and VE-Cadherin was analyzed by RT-PCR. RNA extracted
from whole postnatal mouse heart (mH) was used as a positive control.
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each time 3–5 mice were used.
Cell culture
The Sca-1+-enriched cells were seeded into 0.1% gelatin-
coated 12-well culture plates and cultured in growth
medium [16] composed of EBM-2 medium (EGM-2
Single Quots; Lonza) and M199 medium (Gibco) at the
ratio of 1:3, plus 10% fetal bovine serum (FBS; Gibco),
1% penicillin-streptomycin (P/S; Gibco), 1% MEM nones-
sential amino acids (Gibco), and 10 ng/ml basic fibroblast
growth factor (bFGF; Roche). Cells were cultured at 37°C
in humid air with 5% CO2. Cells were given at least 3 days
to attach before refreshing the medium and were passaged
at 80-90% confluence. Cells were washed with PBS,
detached with 0.25% trypsin-EDTA (Gibco), then split at
ratios from 1:2 to 1:5. When the cells covered a surface
larger than 10 cm2, they were converted to cultures in
normal medium that contained low glucose Dulbecco’s
modified Eagle’s medium (DMEM; Gibco), 10% FBS, and
1% P/S, without bFGF.
Flow cytometry (FCM) analysis
FCM analysis was performed on the whole cardiac cell
suspension filtered through a 40-μm strainer (pre-MACS),
the Sca-1+-enriched cell suspension (post-MACS) and the
flow-through cell suspension (post-MACS) to evaluate the
effectiveness of MACS and the purity of the Sca-1+-
enriched population. The pre-MACS suspension was fur-
ther divided into two equal parts, one of which was used
for a blank control. Other cell preparations were resus-
pended in 100 or 200 μl buffer and incubated with FITC-
conjugated anti-Sca-1 antibody (Miltenyi Biotec) at 4°C
for 30 minutes.
To determine whether the expression of surface markers
in Sca-1+-enriched cells changed during long-term culture
in vitro, cells from three passages (P7, P28 and P53) were
detached using 0.25% trypsin/EDTA solution. Cells fromeach passage were counted and divided into several samples
(1-5 × 105 cells/sample). For immunofluorescence label-
ing, each cell sample was resuspended in 100 μl buffer
and incubated for 30 minutes at 4°C with PE-labeled anti-
Sca-1 (eBioscience), anti-c-kit (CD117; eBioscience), anti-
Flk-1 (eBioscience), anti-CD31 (eBioscience), anti-CD45
(eBioscience) antibodies, or APC-labeled anti-CD34
(eBioscience) antibody with dilutions as suggested by
the manufacturer. The cells were subsequently washed
3 times with buffer, resuspended in 100 μl cold buffer,
then analyzed in a FACSCanto IIflow cytometer (BD
Biosciences). Non-stained cells from each passage were
used as controls. And this experiment was performed
three independent replicates.Differentiation assays
Three cell populations (P7, P28, and P53) were cultured
in specific differentiation medium for induction into
different cardiac cell lineages. Cells were initially seeded
at a density of 1 × 104 cells/cm2 in normal medium, then
converted into specific differentiation medium when they
approached 80-90% confluence. For smooth muscle cell
induction, cells were cultured in normal medium supple-
mented with 10 ng/ml transforming growth factor-β1
(TGF-β1; Peprotech) for 10 days. For endothelial cell
induction, cells were cultured in EBM-2 medium (Lonza)
plus the EGM-2 Single Quots kit (Lonza) but without
hydrocortisone, plus 20 ng/ml vascular endothelial growth
factor-165 (VEGF165, Peprotech), and were grown on
fibronectin-coated dishes for 14 days. For cardiomyocyte
induction, cells were cultured with DMEM/F12 (Gibco)
supplemented with 2% FBS, 2% B27, 100 ng/ml bone mor-
phogenetic protein-2 (BMP-2; Peprotech), and 100 ng/ml
fibroblast growth factor-4 (FGF-4; Peprotech) on gelatin-
coated dishes for 14 days. In control group, cells were
cultured in the same medium for differentiation without
growth factors. All the media were changed every 3 days.
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Cells (P7, P28, P53) were seeded at a density of 1 ×
104 cells/cm2 on 24-well culture plates and cultured in
normal medium at 37°C in humid air with 5% CO2. Cell
counting kit-8 (CCK-8; Dojindo) antigen was added to the
cell supernatant at the ratio of 1:10 for a 2 h incubation
on days 1 (24 hours after initial seeding), 3, 5, 7, and 9.
Subsequently, 100 μl of supernatant from each well was
carefully transferred to a 96-well plate to measure the op-
tical density(OD) value at a wavelength of 450 nm. It was
measured at the five time points with 6 technical repli-
cates of each passage. The living cell number can be indir-
ectly presented by the OD value as they are positively
correlated. And this experiment was also performed three
independent replicates.
Analysis of mRNA expression by reverse transcription
polymerase chain reaction (RT-PCR)
Total RNA was extracted from P7, P28, P53, differentiated
cells, and whole mouse heart tissue using TriZol reagent
(Invitrogen), according to the manufacturer’s instructions.
Integrity of the RNA samples was verified with a Nano-
Drop 2000 (Thermo Scientific). Total purified RNA
samples were treated with RNase-free DNase (Qiagen) to
eliminate DNA contamination and were stored at −80°C
until use. RT-PCR was carried out in two steps, and
reverse transcription was performed using PrimeScript
RTase (TaKaRa). An equal amount of each sample of
cDNA was amplified with 2× Taq Master Mix (OFFO
BioPharm, Shanghai). The primers used for polymerase
chain reaction (PCR) are shown in Additional file 3:
Table S2. The reaction was performed with 38 cycles,
with denaturation at 95°C for 30s, annealing from 54-70°C
for 30s, and extension at 72°C for 30s. After the last cycle,
PCR products were run on a 1-2% agarose TAE gel (OFFO
BioPharm, Shanghai). Expression levels were evaluated by
the intensity of the band stained with ethidium bromide.
Quantified values were normalized against the housekeep-
ing gene, GAPDH. The RT-PCR tests were replicated
three times.
Immunofluorescence (IF) staining
Cells from P7, P28, and P53 were analyzed with IF stain-
ing for the surface markers Sca-1 and CD31. Induced and
control group cells were labeled with IF for cardiac cell
lineage-specific markers. Cells were washed with PBS and
fixed with 4% paraformaldehyde for 15 min at room
temperature (RT), permeabilized if noted with 0.3% Triton
X-100 (Sigma) for 20 min at RT, washed with PBS,
blocked with 10% donkey or rabbit serum (Multisciences
Biotech, China) in PBS for 30 min at 37°C, and then incu-
bated for 2 hours at RT with primary antibodies against
Sca-1 (Millipore), CD31 (eBioscience), cardiac troponin T
(cTNT; Santa Cruz), cardiac-myosin heavy chain (cMHC;Abcam), smooth muscle actin (SMA; Epitomics), smooth
muscle-myosin heavy chain (sMHC; Abcam), or calponin-
1 (Abcam). After rinsing with PBS, cells were subsequently
incubated with Alexa Fluor 488-conjugated donkey or
rabbit-originated secondary antibodies (Life Technologies,
Invitrogen) or PE conjugated streptavidin (eBioscience) for
30 min at RT. Nuclei were counter-stained with DAPI
(1:1000; Enzo) in PBS for 1 min at RT. Immunostaining
was observed and photoed by an inverted fluorescence
microscope (Leica DMI3000B, Germany) and analyzed
by Image-Pro Plus 7.0 software (Media Cybernetics,
America).
Tumorigenic assays
2 × 106 cells from P7, P28, and P53 were injected subcuta-
neously into one dorsal side of severe combined immune
deficiency (SCID) mice. As a positive control, an equal
quantity of mouse R1 embryonic stem (ES) cells were
inoculated subcutaneously into the opposite dorsal side
of the same mice. Details of the cell type, cell concentra-
tion, injection volume and injection points are shown in
Additional file 1: Table S1.
Statistical analysis
All data are expressed as mean ± SD. Significance between
two comparisons was evaluated by independent-samples
T test. Significance between multiple comparisons was
evaluated by one-way ANOVA. Bonferroni post-hoc tests
were used to identify differences. Statistical values were
calculated using the SPSS 17.0 software. A value of P < 0.05
was considered statistically significant.
Additional files
Additional file 1: Table S1. Tumorigenic Assay.
Additional file 2: Figure S1. Quantitative analysis of differentiation
potential of subcultured cells from Sca-1+-enriched populations into cardiac
cell lineages in vitro. A, cMHC or cTNT positive cells were calculated after
induction to cardiomyocyte-like cells. (n = 10). B, SMA, sMHC or calponin
positive cells were calculated after induction to smooth muscle-like cells.
(n = 10). C, CD31 positive cells were calculated after induction to
endothelial-like cells. (n = 10). The positive rate was presented as ratio of
positive cell number to total cell number (*p < 0.01 vs control).
Additional file 3: Table S2. Primers used for reverse transcription PCR.
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